The US FDA Reverses Decision And Allows Oxitriptan Compounding For Now

 
• By Joanne S. Eglovitch
  
Side view of titration in a compounding pharmacy
Appeal gained reprieve for oxitriptan

More from Manufacturing

More from Compliance